Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1637-1653
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1637
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1637
Figure 2 Caldesmon and resistance to various modalities of cancer therapy.
INF: Interferon; JAK/STAT: Janus kinase/signal transducers and activators of transcription; PD-L1: Programmed death ligand 1; PD-1: Programmed death 1; 5-Fu: 5-fluorouracil; TGF: Transforming growth factor; ER: Estrogen receptor; NF-κB: Nuclear factor kappa B.
- Citation: Alnuaimi AR, Nair VA, Malhab LJB, Abu-Gharbieh E, Ranade AV, Pintus G, Hamad M, Busch H, Kirfel J, Hamoudi R, Abdel-Rahman WM. Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers. World J Gastrointest Oncol 2022; 14(9): 1637-1653
- URL: https://www.wjgnet.com/1948-5204/full/v14/i9/1637.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i9.1637